IRWD
insider transactionsIRONWOOD PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-7.1M
0 buy · 7.1M sell
Net value · 365d
-$22.0M
$0 in · $22.0M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
16
0 buy · 7.1M sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
63.5K sh
Own +37%
-
Grant·A
Director
$0
63.5K sh
Own +38%
-
Sell·S
Director · 10b5-1
$80.5K
21.6K sh · $3.73
Own -8%
-
Grant·A
Director · 10b5-1
$0
63.5K sh
Own +30%
-
Grant·A
Director
$0
63.5K sh
Own +54%
-
Grant·A
Director
$0
63.5K sh
Own +33%
-
Grant·A
Director
$0
63.5K sh
Own +24%
-
Grant·A
Director
$0
63.5K sh
Own +10%
-
Grant·A
Director
$0
4.1K sh
Own +2%
-
Grant·A
PFO & PAO
$0
25.0K sh
Own +6%
-
Sell·S
Director
$19.2K
5.8K sh · $3.31
Own -0%
-
Sell·S
Director
$20.5M
6.7M sh · $3.05
Own -42%
-
Grant·A
Director
$0
4.5K sh
Own +2%
-
Grant·A
SVP, CMO, Head-Res&Drug
$0
136.6K sh
Own +26%
-
Grant·A
Principal Accounting Officer
$0
163.9K sh
Own +65%
-
Grant·A
Chief Legal Officer
$0
136.6K sh
Own +38%
-
Grant·A
Chief Financial Officer
$0
136.6K sh
Own +85%
-
Grant·A
Thomas A Mccourt KEY
Chief Executive Officer
$0
409.8K sh
Own +28%
-
Grant·A
Chief Commercial Officer
$0
136.6K sh
Own +64%
-
Sell·S
Chief Financial Officer
$41.9K
11.5K sh · $3.66
Own -7%
-
Sell·S
Chief Legal Officer
$69.7K
19.1K sh · $3.66
Own -5%
-
Sell·S
SVP, CMO, Head-Res&Drug
$62.3K
17.0K sh · $3.66
Own -3%
-
Sell·S
Thomas A Mccourt KEY
Chief Executive Officer
$378.9K
103.5K sh · $3.66
Own -7%
-
Sell·S
Principal Accounting Officer
$46.2K
12.6K sh · $3.66
Own -5%
-
Sell·S
Chief Commercial Officer
$41.1K
11.2K sh · $3.66
Own -5%
-
Sell·S
Chief Financial Officer
$40.0K
10.5K sh · $3.81
Own -6%
-
Sell·S
Chief Legal Officer
$66.4K
17.4K sh · $3.81
Own -4%
-
Sell·S
SVP, CMO, Head-Res&Drug
$59.3K
15.6K sh · $3.81
Own -3%
-
Sell·S
Thomas A Mccourt KEY
Chief Executive Officer
$361.0K
94.8K sh · $3.81
Own -6%
-
Sell·S
Principal Accounting Officer
$44.0K
11.6K sh · $3.81
Own -4%
-
Sell·S
Chief Commercial Officer
$39.2K
10.3K sh · $3.81
Own -4%
-
Sell·S
Principal Accounting Officer · 10b5-1
$162.9K
35.4K sh · $4.60
Own -11%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Jay Shepard | Grant A | 63.5K | $0 |
| Jun 16, 2026 | Marla L Kessler | Grant A | 63.5K | $0 |
| Jun 16, 2026 | Julie Mchugh 10b5-1 | Sell S | 21.6K | $80.5K |
| Jun 16, 2026 | Julie Mchugh 10b5-1 | Grant A | 63.5K | $0 |
| Jun 16, 2026 | Catherine Moukheibir | Grant A | 63.5K | $0 |
| Jun 16, 2026 | Jon R Duane | Grant A | 63.5K | $0 |
| Jun 16, 2026 | Alexander J Denner | Grant A | 63.5K | $0 |
| Jun 16, 2026 | Mark G Currie | Grant A | 63.5K | $0 |
| Jun 15, 2026 | Alexander J Denner | Grant A | 4.1K | $0 |
| May 19, 2026 | Ronald Silver | Grant A | 25.0K | $0 |
| Mar 17, 2026 | Alexander J Denner | Sell S | 5.8K | $19.2K |
| Mar 17, 2026 | Alexander J Denner | Sell S | 6.7M | $20.5M |
| Mar 13, 2026 | Alexander J Denner | Grant A | 4.5K | $0 |
| Mar 10, 2026 | Michael Shetzline | Grant A | 136.6K | $0 |
| Mar 10, 2026 | Ronald Silver | Grant A | 163.9K | $0 |
| Mar 10, 2026 | Minardo John | Grant A | 136.6K | $0 |
| Mar 10, 2026 | Gregory S. Martini KEY | Grant A | 136.6K | $0 |
| Mar 10, 2026 | Thomas A Mccourt KEY | Grant A | 409.8K | $0 |
| Mar 10, 2026 | Tammi L Gaskins | Grant A | 136.6K | $0 |
| Feb 24, 2026 | Gregory S. Martini KEY | Sell S | 11.5K | $41.9K |
| Feb 24, 2026 | Minardo John | Sell S | 19.1K | $69.7K |
| Feb 24, 2026 | Michael Shetzline | Sell S | 17.0K | $62.3K |
| Feb 24, 2026 | Thomas A Mccourt KEY | Sell S | 103.5K | $378.9K |
| Feb 24, 2026 | Ronald Silver | Sell S | 12.6K | $46.2K |
| Feb 24, 2026 | Tammi L Gaskins | Sell S | 11.2K | $41.1K |
| Feb 23, 2026 | Gregory S. Martini KEY | Sell S | 10.5K | $40.0K |
| Feb 23, 2026 | Minardo John | Sell S | 17.4K | $66.4K |
| Feb 23, 2026 | Michael Shetzline | Sell S | 15.6K | $59.3K |
| Feb 23, 2026 | Thomas A Mccourt KEY | Sell S | 94.8K | $361.0K |
| Feb 23, 2026 | Ronald Silver | Sell S | 11.6K | $44.0K |
| Feb 23, 2026 | Tammi L Gaskins | Sell S | 10.3K | $39.2K |
| Jan 5, 2026 | Ronald Silver 10b5-1 | Sell S | 35.4K | $162.9K |
About IRWD insider trading
This page tracks insider transactions for IRONWOOD PHARMACEUTICALS INC (IRWD) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.